Note 9 - Statera License Agreement (Details Textual) $ in Thousands	Jul. 31, 2026 shares	Mar. 28, 2025 USD ($)	Feb. 11, 2025 USD ($) kg	Jun. 30, 2026 USD ($)	Dec. 31, 2025 USD ($)	Jun. 18, 2025 USD ($)
Accrued Expense, Capitalized License Cost				$ 750	$ 0
Amended and Restated Exclusive License Agreement [Member]
License Agreement, Maximum Lien Payoff Amount						$ 5,600
Amended and Restated Exclusive License Agreement [Member] | Statera [Member]
Subordinated Debt, Percent Received						20.00%
Amended and Restated Exclusive License Agreement [Member] | Avenue [Member]
Subordinated Debt, Percent Received						80.00%
Statera License Agreement [Member]
Asset Acquisition, Consideration Transferred			$ 1,500
Payments to Acquire Productive Assets			300
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable			1,200
Asset Acquisition, Consideration Transferred, Transaction Cost			243
Capitalized Cost, Additional License Costs				750
Accrued Expense, Capitalized License Cost				$ 750
Statera License Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares) | shares	1,288
Statera License Agreement [Member] | Drug Substance Care, Storage, and Handling Lease [Member]
Lessee, Operating Lease, Annual Lease Payments			$ 1
Statera License Agreement [Member] | Drug Substances [Member]
Inventory, Finished Goods and Work in Process, Mass, Net (Kilogram) | kg			15
Statera License Agreement, Neutropenia Option [Member]
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable		$ 500
Asset Acquisition, Contingent Consideration, Tranche One		$ 500